Catalyst Pharma Q3: Strong Royalties, Capital Gains

TL;DR

Catalyst Pharma Q3 shows strong royalty income, over $100M and $500M reported, with Firdapse driving sales.

AI Summary

Catalyst Pharmaceuticals, Inc. reported its third quarter 2024 results for the period ending September 30, 2024. The company's revenue from sales of Firdapse and other products is detailed, with specific royalty amounts exceeding $100 million and $500 million mentioned for the period. The filing also references significant additional paid-in capital and customer concentration risks.

Why It Matters

This filing provides insight into Catalyst Pharmaceuticals' financial performance and revenue streams, particularly concerning their key drug Firdapse, which is crucial for investors and the market.

Risk Assessment

Risk Level: medium — The filing highlights customer concentration risk, indicating a potential dependency on a few key customers for revenue.

Key Numbers

• $100M+ — Royalty Revenue (Indicates significant income from royalties, exceeding $100 million.)
• $500M+ — Royalty Revenue (Further specifies a higher tier of royalty income, exceeding $500 million.)
• 2024-09-30 — Reporting Period End Date (Defines the end of the fiscal quarter for which financial data is reported.)

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of reporting period
• 355 ALHAMBRA CIRCLE (location) — Company's business and mailing address
• CORAL GABLES (location) — City of company's address
• Firdapse (product) — Key drug product mentioned
• RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember (financial_metric) — Specific royalty range reported
• RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember (financial_metric) — Specific royalty range reported
• AdditionalPaidInCapitalMember (financial_metric) — Capital reported
• CustomerConcentrationRiskMember (risk_factor) — Identified risk

FAQ

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share CPRX NASDAQ Capital Marke

Filing Documents

• cprx-20240930.htm (10-Q) — 2102KB
• cprx-ex31_1.htm (EX-31.1) — 13KB
• cprx-ex31_2.htm (EX-31.2) — 13KB
• cprx-ex32_1.htm (EX-32.1) — 9KB
• cprx-ex32_2.htm (EX-32.2) — 9KB
• 0000950170-24-122282.txt ( ) — 9888KB
• cprx-20240930.xsd (EX-101.SCH) — 1304KB
• cprx-20240930_htm.xml (XML) — 1955KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Consolidated balance sheets at September 30, 2024 (unaudited) and December 31, 2023 3 Consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024 and 2023 (unaudited) 4 Consolidated statements of changes in stockholders' equity for the three and nine months ended September 30, 2024 and 2023 (unaudited) 5 Consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023 (unaudited) 7 Notes to unaudited consolidated financial statements 8 Item 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 33 Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK 47 Item 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 47

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 48 Item 1A.

RISK FACTORS

RISK FACTORS 48 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 49 Item 3. DEFAULTS UPON SENIOR SECURITIES 49 Item 4. MINE SAFETY DISCLOSURE 49 Item 5. OTHER INFORMATION 49 Item 6. EXHIBITS 50

SIGNATURES

SIGNATURES 51 2 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED BALA NCE SHEETS (in thousands, except share data) September 30, 2024 December 31, 2023 (unaudited) ASSETS Current Assets: Cash and cash equivalents $ 442,331 $ 137,636 Accounts receivable, net 58,266 53,514 Inventory 20,017 15,644 Prepaid expenses and other current assets 18,384 12,535 Total current assets 538,998 219,329 Operating lease right-of-use asset, net 2,301 2,508 Property and equipment, net 1,380 1,195 License and acquired intangibles, net 166,016 194,049 Deferred tax assets, net 48,473 36,544 Investment in equity securities 14,842 16,489 Total assets $ 772,010 $ 470,114 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 11,563 $ 14,795 Accrued expenses and other liabilities 93,832 61,268 Total current liabilities 105,395 76,063 Operating lease liability, net of current portion 2,889 3,188 Other non-current liabilities 2,785 2,982 Total liabilities 111,069 82,233 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.001 par value, 5,000,000 shares authorized: none issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value, 200,000,000 shares authorized; 119,266,561 shares and 107,121,549 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 119 107 Additional paid-in capital 431,597 266,488 Retained earnings 229,225 121,272 Accumulated other comprehensive income (Note 4) — 14 Total stockholders' equity 660,941 387,881 Total liabilities and stockholders' equity $ 772,010 $ 470,114 The accompanying notes are an integral part of these consolidated financial statements. 3 Table of Contents CATALYST PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATI ON

View Full Filing

View this 10-Q filing on SEC EDGAR